カテゴリ： GlobalData, アメリカ, 企業調査

Tocagen Inc (TOCA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Tocagen Inc (TOCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8107
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer. The company offers lead product candidate such as Toca 511 and Toca FC, which is being investigated for the treatment of recurrent and metastatic cancers. It uses cancer-selective gene therapy platform built on retroviral replicating vectors (RRVs) which are designed to deliver therapeutic genes into the DNA of cancer cells. The company is developing Toca 511 and Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. It also offers other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen is headquartered in San Diego, California, the US.

Tocagen Inc (TOCA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tocagen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tocagen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Tocagen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tocagen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Tocagen Raises USD2.73 Million in Venture Financing 12
Tocagen Raises USD8.3 Million in Extended Venture Financing 13
Tocagen Raises US$0.2 Million In Venture Financing 14
Tocagen Raises Additional US$8 Million In Venture Financing 15
Partnerships 16
RiboMed Biotech Enters into Research Agreement with Tocagen 16
Licensing Agreements 17
Beijing Apollo Venus Biomedical Technology Enters into Licensing Agreement with Tocagen 17
Equity Offering 18
Tocagen Plans to Raise up to USD100 Million in Public Offering of Shares 18
NanoCarrier Agrees to Invest in Tocagen 19
Tocagen Raises USD97.8 Million in IPO 20
Tocagen Inc – Key Competitors 22
Tocagen Inc – Key Employees 23
Tocagen Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 07, 2018: Tocagen announces second quarter 2018 financial and business results 25
May 10, 2018: Tocagen Reports First Quarter 2018 Financial and Business Results 27
Mar 08, 2018: Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results 29
Nov 08, 2017: Tocagen Reports Third Quarter 2017 Financial and Business Results 31
Aug 09, 2017: Tocagen Reports Second Quarter 2017 Financial and Business Results 33
May 23, 2017: Tocagen Reports First Quarter 2017 Financial and Business Results 35
Corporate Communications 36
Dec 14, 2017: Tocagen Added to NASDAQ Biotechnology Index 36
Mar 07, 2017: Tocagen Appoints Mark Foletta as Executive Vice President and Chief Financial Officer 37
Government and Public Interest 38
Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 38
Product News 40
02/23/2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma 40
01/13/2017: Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea 41
Product Approvals 42
Jul 24, 2017: Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma 42
Clinical Trials 43
May 14, 2018: Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 511 & Toca FC at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) 43
May 14, 2018: Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) 44
Apr 25, 2018: Immunotherapy Clinical Trial Reveals Brain Tumor Shrinkage, Continues with Phase 3 Study 45
Apr 17, 2018: Tocagen to Present Updated Clinical and Preclinical Data at The Three Scientific Conferences 46
Apr 16, 2018: Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018 47
Mar 15, 2018: Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 48
Nov 09, 2017: Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences 49
Oct 27, 2017: Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma 51
Oct 26, 2017: Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 Trial 53
Oct 17, 2017: Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 54
Jun 19, 2017: Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagens Toca 511 & Toca FC 55
May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting 56
Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia 57
Feb 23, 2017: Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Tocagen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tocagen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tocagen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tocagen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Tocagen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tocagen Raises USD2.73 Million in Venture Financing 12
Tocagen Raises USD8.3 Million in Extended Venture Financing 13
Tocagen Raises US$0.2 Million In Venture Financing 14
Tocagen Raises Additional US$8 Million In Venture Financing 15
RiboMed Biotech Enters into Research Agreement with Tocagen 16
Beijing Apollo Venus Biomedical Technology Enters into Licensing Agreement with Tocagen 17
Tocagen Plans to Raise up to USD100 Million in Public Offering of Shares 18
NanoCarrier Agrees to Invest in Tocagen 19
Tocagen Raises USD97.8 Million in IPO 20
Tocagen Inc, Key Competitors 22
Tocagen Inc, Key Employees 23

List of Figures
Tocagen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tocagen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tocagen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tocagen Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Tocagen Inc (TOCA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Famous Brands Limited (Foodservice)：企業の戦略・SWOT・財務情報
    Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • DISH Network Corp (DISH)：企業の財務・戦略的SWOT分析
    DISH Network Corp (DISH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Daito Trust Construction Co., Ltd.：企業の戦略・SWOT・財務分析
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Boston Beer Company, Inc. (SAM)：企業の財務・戦略的SWOT分析
    The Boston Beer Company, Inc. (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • NeuroMetrix Inc (NURO)-医療機器分野：企業M&A・提携分析
    Summary NeuroMetrix Inc (NeuroMetrix) is a medical device company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, SENSUS pain therapy device, NC-stat DPNChe …
  • Rallis India Ltd (RALLIS)：企業の財務・戦略的SWOT分析
    Summary Rallis India Ltd (Rallis), a subsidiary of Tata Chemicals Ltd, is an agri-solutions service provider. The company’s business portfolio includes domestic crop protection, international business, contract manufacturing, seeds, plant growth nutrients and agri services. Its products portfolio in …
  • Qiagen NV (QIA)：医療機器：M&Aディール及び事業提携情報
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify …
  • Midwest Energy Cooperative：企業の戦略的SWOT分析
    Midwest Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • The Coca-Cola Co：戦略・SWOT・企業財務分析
    The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report Summary The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • InterHealth Nutraceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary InterHealth Nutraceuticals Inc (InterHealth), a subsidiary of Lonza Group Ltd, is a developer, manufacturer and distributor of nutraceutical ingredients. The company offers nutritional ingredients such as Zychrome, Meratrim, LOWAT, Super CitriMax, ChromeMate, L-OptiZinc, Protykin, ZMA, UC-II …
  • Avanti Feeds Ltd (AVANTIFEED)：企業の財務・戦略的SWOT分析
    Avanti Feeds Ltd (AVANTIFEED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Excision BioTherapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Excision BioTherapeutics Inc (Excision BioTherapeutics) is a developer of gene editing therapeutics for the treatment of infectious diseases. The company’s products comprise EBT101, a HIV CRISPR Cas9 gRNA multiplex biologic for the prevention of Human Immunodeficiency Virus; EBT103, a PML JC …
  • Star Buffet, Inc (STRZ)：企業の財務・戦略的SWOT分析
    Star Buffet, Inc (STRZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • The Saudi British Bank (1060)：企業の財務・戦略的SWOT分析
    The Saudi British Bank (1060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Apotex Inc-製薬・医療分野：企業M&A・提携分析
    Summary Apotex Inc (Apotex) produces and markets a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacture and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medical use. The company has research and d …
  • Woori Bank：企業の戦略・SWOT・財務情報
    Woori Bank - Strategy, SWOT and Corporate Finance Report Summary Woori Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Messer Cutting Systems GmbH：企業の戦略的SWOT分析
    Messer Cutting Systems GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • CorVel Corporation：企業の戦略・SWOT・財務情報
    CorVel Corporation - Strategy, SWOT and Corporate Finance Report Summary CorVel Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Premera Blue Cross：企業の戦略的SWOT分析
    Premera Blue Cross - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Houston Methodist Hospital：企業の戦略的SWOT分析
    Houston Methodist Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆